Compassionate Cancer Care Inc, serving Orange County and the Inland Empire

Publicatons:
 

Alrwas A, Dellafosse O. (2009, September 28). Sporadic Burkitt Lymphoma presenting with hepatosplenomegaly. UT - Houston Journal of Internal Medicine.

 

Choi B, Robins HI, Schiller J, Mehta M. A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer. Cancer Chemother Pharmacol. 2008 Dec;63(1):175-9. 

 

Choi BS, Robins HI. Primary disease resection in metastatic breast cancer improves survival. J Clin Oncol. 2007 Feb 10;25(5):603-4.

 

Pan J et al. Choriocarcinoma Mimicking Pulmonary Miliary Tuberculosis.A Case Report. Poster presentation, American College of Physicians Annual Meeting – San Diego, CA April 2017.

 

Salimi-Tari P, Abramson N, Skin lesions and mast cells, Blood 2008;112: 28. Jasani N, Salimi-Tari P, Rana F, Complete remission of metastatic Ewing’s sarcoma/primitive neuroectodermal tumor with standard chemotherapy, Community Oncology 2007; 4(9): 567-568. 

 

Kumar et al. "Bioartificial Muscle Models in Microgravity Environments" NASA Aerospace Medicine and Occupational Health Branch. Kennedy Space Center, Cape Canaveral, Florida 2008.

 

Choi BS, Sondel PM, Hank JA, et al. Phase I trial of combined treatment with ch 14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother. 2006 Jul;55(7):761-74.

 

Wei L, Cui L, Snider B, Rivkin M, Yu SS, Lee C, Adams L, Gottlieb D, Johnson E, Choi D. Transplantation of Embryonic Stem Cells Overexpressing Bcl-2 Promotes Functional Recovery after Transient Cerebral Ischemia. Neurobiology of Disease. 2005 (19) 183-193.

 

Alrwas A, Arnaout A,. (2006, May 30). Acid-base balance & principles of compensation. University of Damascus Publications.

 

Knight MA, Kennerson ML, Anney RJ, Matsuura T, Nicholson GA, Salimi-Tari P, Gardner RJ, Storey E, Forrest SM, Spinocerebellar ataxia type 15 (sca15) maps to 3p24.2-3pter: exclusion of the ITPR1 gene, the human orthologue of an ataxic mouse mutant, Neurobiol Dis. 2003;13(2):147-57. 

 

H.Jhangiani, G.R.Justice, et al. Evaluation of Docetaxel and Cisplatin with Filgrastim Support for the treatment of Patients With Stage III or IV Non-small Cell Lung Cancer. American Society of Clinical Oncology, San Francisco, California, May 2001.

 

Salimi-Tari P, Cheung M, Safar CA, Tracy JT, Tran I, Harbers K, Breindl M, Molecular cloning and chromatin structure analysis of the murine alpha1(I) collagen gene domain, Gene 1997;198(1-2):61-72. 

 

Nagourney RA, Baqai R, Atiba J, Iyer, P, Ciarolla A, Blitzer J. Pala plus 5-FU/ Leucovorin in Advanced Gastric and Pancreatic Cancer. [abstract] In: Proceedings of ASCO Annual Meeting; 1994 May 14th-17th; Dallas, Texas

 

R. Guerrero, G.Justice, D. Rounds, K. Shah, H. Jhangiani, N. Tchekmedyan, P. Coluzzi, F. Dexeus,T. White, E. Bald. Ring-Shaped Particle (RSP): A Tumor Marker for Lung and Ovarian Cancer Correlates Well as a Parameter of Tumor Response to Therapy: American Society of Clinical Oncology, Orlando, Florida, April, 1993.

 

R. Guerrero, G. Justice, D. Rounds, K. Shah, H. Jhangiani, N.Tchekmedyian, P. Coluzzi, F. Dexeus, T. White, E. Bald.  Ring-Shaped Particle (RSP): An Accurate Tumor marker for Breast, Lung and Ovarian Carcinoma: European Association of Cancer Research, 12th Annual Meeting, Brussels, Belgium, April, 1993.

Su DW, Pasch W, Costales C, Siddiqi I, Mohrbacher A. A Case of Asian Variant Intravascular Large Cell Lymphoma in an African American Male. Proc (Bayl Univ Med Cent). 2017 Apr; 30(2): 186–189.

Su DW, Nieva J. Biophysical technologies for understanding circulating tumor cell biology and metastasis. Transl Lung Cancer Res 2017;6(4):473-485.

 

Andrade J, Wentzel K, Yu SS, Shi S, Merchant A, Ballas L. Mucositis following HSCT with myeloablative TBI based on GVHD prophylaxis regimen [ abstract]  In: Proceedings of the Annual Meeting Program Committee of the American Society for Radiation Oncology (ASTRO); 2017 Sept 24-27;San Diego, CA. ASTRO; 2017. Abstract nr 3008.

 

Yu SS, Athreya K, Liu, SV, Schally AV, Groshen S, Tsao-Wei D, Quinn D, Dorff T, Xiong S, Engel J, Pinski J.

 

A Phase II trial of AEZS-108 in Castration and Taxane Resistant Prostate Cancer A Phase II trial of AEZS-108 in Castration and Taxane Resistant Prostate Cancer. Clinical Genitourinary Cancer. 2017 Dec;15(6):742-749.

 

Yu SS, Dorff TB, Ballas LK, Sadeghi S, Skinner EC, Quinn DI. Immunotherapy in Urothelial Cancer, Part 1: T-Cell Checkpoint Inhibition in Advanced or Metastatic Disease. Clinical Advances in Hematology & Oncology. Volume 15, Issue 6 June 2017.

 

Yu SS, Dorff TB, Ballas LK, Sadeghi S, Skinner EC, Quinn DI. Immunotherapy in Urothelial Cancer, Part 2: Adjuvant, Neoadjuvant, and Adjunctive Treatment. Clinical Advances in Hematology & Oncology Volume 15, Issue 7 July 2017.

Yu, SS, Schally AV, Groshen S, Denice TW, Liu SV, Quinn D, Dorff T, Athreya K, Xiong S., Pinski J. Updated results for phase II trial of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer [abstract] In: Proceedings of ASCO's Genitourinary Cancers Symposium; 2017 Feb 16- Feb 18; Orlando, Fl: Abstract nr 178928.

Su DW, Mita M, Mita AC. (2016). The Clinical Pharmacology and Toxicity Profile of Rapalogs, in Mita M, Mita A, and Rowinsky KE, eds., mTOR Inhibition for Cancer Therapy: Past, Present and Future: Paris, Springer Paris, p. 161-189.

Yu SS, Quinn D, Dorff T. Clinical use of cabozantinib in the treatment of advanced kidney cancer: Efficacy, safety and patient selection. OncoTargets and Therapy. 2016 Sept 23;9:5825-5837.

    

Yu SS, Garcia AA. Advancements in Recurrent and Metastatic Cervical Cancer. Am J Hematol Oncol. 2015;11(1):26-31.

 

Pinski J, Schally AV, Groshen S, Denice TW, Liu SV, Quinn D, Dorff T, Athreya K, Yu SS, Xiong S. A phase II trial of AEZS-108 in castration and taxane resistant prostate cancer." European Journal of Cancer. 2015 Sept: 51: S488. Abstract nr 2539.

 

Shabihkhani M, Yu SS, Yang D, Lin S, Hamilton AS, Lenz HJ, Barzi A. Treatment outcomes of metastatic colorectal cancer in a Hispanic population. Clinical Colorectal Cancer. 2015 Mar 31.  

 

Johnson JA, Yu SS, Elist M, Arkfeld D, Panush RS. Rheumatologic manifestations of the "MonoMAC" syndrome. a systematic review. Clin Rheumatol. 2015 Sep;34(9):1643-5. 

 

Yu SS, Chaudry B. Approach to Squamous Cell Carcinoma of the Neck causing recurrent syncope and persistent bradycardia [ abstract] In: Proceedings of the California-Hawaii Society of General Internal Medicine Meeting; 2013 Feb 2; Los Angeles, CA. SGIM; 2013. Abstract nr 7807.

 

Kumar, Avishek, et al. "An Unusual Ingestion in an Older Person: Dentures" Journal of

the American Geriatrics Society 62.2 (2014): 399-400.

 

Alrwas, A, et al. Phase I Trial of Biochemotherapy with Cisplatin, Temozolomide and dose escalation of Nab-Paclitaxel combined with Interleukine-2 and interferon-a in patients with metastatic melanoma. Melanoma research Journal. April 16th 2014.  

 

Stiller JW, Yu SS, Brenner LA, et al. Sparring and Neurological Function in Professional Boxers. Frontiers in Public Health. 2014;2:69. 

 

Alrwas, A, et al. Tumor-Infiltrating Lymphocyte (TIL) growth as a prognostic factor in patients (pts) with metastatic melanoma (mM).  Poster presentation. The Stephenson Cancer Center Research Symposium Jan 2014.

 

Li WL, Yu SP, Chen D, Yu SS, Jiang YJ, Genetta T, Wei L. The Regulatory Role of NF-κB in Autophagy-like Cell Death after Focal Cerebral Ischemia in Mice. Neuroscience. 2013 Aug 6; 244:16-30.

Su DW, Kashefi M, Glassman PA. Head and Neck Lymphadenopathy in a Young Man. Proceedings of UCLA HealthCare 2013.

Alrwas, A, et al. Tumor-Infiltrating Lymphocyte (TIL) growth as a prognostic factor in patients (pts) with metastatic melanoma (mM).  Poster presentation. Melanoma Congress 2013.

 

Alrwas, A, et al. Tumor-Infiltrating Lymphocyte (TIL) growth as a prognostic factor in patients (pts) with metastatic melanoma (mM).  Poster presentation. Melanoma Congress 2013.

 

Yu SS, Shabihkhani M, Yang D, Thara E, Senagore A, Lenz HJ, Sadeghi S, Barzi A (2013) Timeliness of Adjuvant Chemotherapy for Stage III Adenocarcinoma of the Colon: A Measure of Quality of Care. Clinical Colorectal Cancer Journal. 2013 Dec;12(4):275-9.

 

Shabihkhani M, Yu SS, Yang D, Lenz HJ, Barzi A. Hispanic race and outcome of metastatic (MET) colorectal cancer (CRC): Biology or health care (HC) setting? [abstract]. Journal of Clinical Oncology. 2013 Jul; 31(suppl): abstr e17559.

 

Barzi A, Shabihkhani M, Yu SS, Yang D, Ji L, Lenz HJ. Racial disparities and the outcome of metastatic (met) colorectal cancer (CRC) [ abstract]  In: Proceedings of the 10th Annual Gastrointestinal Cancers Symposium; 2013 Jan 24-26; San Fransico, CA. ASCO; 2013. Abstract nr 373.

Yu SS, Spicer DV, Hawes D, Tseng CC, Yang CS, Pike MC, Wu AH. Biological effects of green tea capsule supplementation in pre-surgery postmenopausal breast cancer patients. Front Oncol. 2013 Dec 13;3:298.

Hemophilia and Hemostasis: A Case-Based Approach to Management, 2nd edition. Edited by Alice D. Ma, Harold R. Roberts, Miguel A. Escobar.  ISBN: 978-0-470-65976-2 . December 2012, Wiley-Blackwell. A contributor/ book chapter

 

Alrwas A, et al. Polycythemia Vera concurrent with FIPL1-PDGFRA positive myeloproliferative neoplasm with eosinopilia, Cancer Genetics Journal. 2012Oct;205(10):519-22.

 

Yu SS, Spicer D, Hawes D, Tseng C, Wu A. Biological Effects of Green Tea Capsule Supplementation in Pre-surgery Breast Cancer Patients [abstract] In: Proceedings of Thirty- Fifth Annual CTRC-AACR San Antonio Breast Cancer Symposium, 2012, Dec  4- 8; San Antonio, Texas. CTRC-AACR 2012. Abstract nr 982.

 

Alrwas A, et al. Phase I study of nab-paclitaxel in combination with biochemotherapy in patients with metastatic melanoma. ASCO June 2012.

 

Yu SS, Shabihkhani M, Sadeghi S, Lenz HJ, Barzi A, Yang D,  Senagore A. Timeliness of Adjuvant Chemotherapy for Stage III Adenocarcinoma of the Colon: A Measure of Quality of Care [ abstract] In: Proceedings of ASCO's Quality Care Symposium; 2012 Nov 30- Dec 1; San Diago, CA: AACR, 2012. Abstract nr 282.

 

Yu SS, Shabihkani M, Yang D, Barzi A. Single institution analysis of disparities in colon rectal cancer in Hispanics and Non-Hispanics [abstract] In: Proceedings of Fifth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, 2012 Oct 27-30; San Diego, California. AACR 2012. Abstract nr A22.

 

Kumar, Avishek, et al. "Characteristics of colorectal cancer in the human

immunodeficiency virus-infected African American population" Medical Oncology 29.3(2012): 1773-1779.

 

Pan, J, Mott M, Bixin Xi, Hepner E, Guan M, et al.  Phase I study of Nelfinavir in Liposarcoma. Cancer Chemotherapy in Pharmacology. 2012 Dec; 70 (6); 791-799 

 

Alrwas A, et al. Polycythemia Vera concurrent with FIP1L1-PDGFRA positive myeloproliferative neoplasm with eosinophilia. A Case Report. Poster presentation, 2nd Annual Advances in Oncology – From Clinical Science to Clinical Practice conference in Memorial Hermann – Texas Medical Center, November 2011.

 

Modi, Y, Kumar A, Shaaban H, et al (June 2011) Colon adenocarcinoma and the human immunodeficiency virus in the HAART era: A retrospective tricenter analysis.  J Clin Oncol 29: 2011 (suppl; abstr e14098).

 

Alrwas A, O’Brien S, CLL Patient Develops CMPD with Eosinophilia. Abstract & Poster presentation , ACP April 2011, San Diego, California.

 

Alrwas A, Escobar MA, Prostate Cancer and coagulopathy: DIC Vs Hyperfibrinolusis. Abstract & Poster Presentation, Regional ACP March 2011, Baylor College of Medicine, Houston, Texas.

 

Kumar, A., Shaaban H. et al. (October 2010). "Citrobacter freundii-induced

Cold Agglutinin Hemolysis" Annals of Hematology Jul;90(7):855-6.

 

Choi BS, Alberti DB, Schelman WR et al. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemother Pharmacol. 2010 Oct;66(5):973-80. 

Meyers JA, Su DW, Lerner A. Chronic Lymphocytic Leukemia and B and T Cells Differ in Their Response to Cyclic Nucleotide Phosphodiesterase Inhibitors. J Immunol 2009; 182: 5400-5411.